The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC


In an analysis comparing real-life outcomes, interferon-a demonstrated more profound hematologic responses compared with hydroxyurea in select patients with myeloproliferative neoplasms. Additionally, molecular responses to therapy were limited to those patients who received IFN-a.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.